| P2093 | author name string | Yunguang Tong | |
| | Jimin Liang | |
| | Cuiqi Zhou | |
| | Vladimir A Ljubimov | |
| | Zhen Qin | |
| P2860 | cites work | Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing | Q46302330 |
| | Size distributions of maternal and fetal DNA in maternal plasma. | Q47432593 |
| | Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls | Q47831743 |
| | Digital karyotyping | Q22066241 |
| | Cancer genome landscapes | Q22242276 |
| | Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients | Q24561669 |
| | Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer | Q24563539 |
| | Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | Q24604601 |
| | Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations | Q24678861 |
| | Digital PCR | Q24685020 |
| | Liquid biopsies: genotyping circulating tumor DNA | Q27010159 |
| | Evolution of the cancer genome | Q27020991 |
| | Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 |
| | Methylation of cell-free circulating DNA in the diagnosis of cancer | Q28085699 |
| | Quantitative and sensitive detection of rare mutations using droplet-based microfluidics | Q28238121 |
| | Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA | Q28239638 |
| | High-throughput droplet digital PCR system for absolute quantitation of DNA copy number | Q28251729 |
| | Development of personalized tumor biomarkers using massively parallel sequencing | Q28278819 |
| | Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing | Q28280303 |
| | Circulating mutant DNA to assess tumor dynamics | Q28289337 |
| | Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers | Q28484970 |
| | Winnowing DNA for rare sequences: highly specific sequence and methylation based enrichment | Q28732084 |
| | The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers | Q29395525 |
| | Analysis of circulating tumor DNA to monitor metastatic breast cancer | Q29614797 |
| | Detection of circulating tumor DNA in early- and late-stage human malignancies | Q29615778 |
| | Tumor metastasis: molecular insights and evolving paradigms | Q29615908 |
| | Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA | Q29620083 |
| | Detection and quantification of rare mutations with massively parallel sequencing | Q30472217 |
| | The origin of elevated levels of circulating DNA in blood plasma of premature neonates | Q33374139 |
| | Identification of microbial DNA in human cancer | Q33441903 |
| | Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer | Q33507538 |
| | An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. | Q33590850 |
| | Tumor heterogeneity: causes and consequences | Q33624298 |
| | Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients | Q33743256 |
| | High fragmentation characterizes tumour-derived circulating DNA. | Q34016528 |
| | Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system | Q34086089 |
| | About the possible origin and mechanism of circulating DNA apoptosis and active DNA release | Q34100424 |
| | Detection and quantification of mutations in the plasma of patients with colorectal tumors | Q34132363 |
| | Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. | Q34139666 |
| | Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations. | Q34207746 |
| | Excretion of deoxyribonucleic acid by lymphocytes stimulated with phytohemagglutinin or antigen | Q34211237 |
| | Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. | Q34278191 |
| | The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. | Q34317490 |
| | High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. | Q34340492 |
| | Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing | Q34382581 |
| | Rapid clearance of fetal DNA from maternal plasma | Q34388637 |
| | Microsatellite alterations in serum DNA of head and neck cancer patients | Q34394745 |
| | Multiparametric analysis of cell-free DNA in melanoma patients | Q34499759 |
| | Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats | Q34530414 |
| | Neoplastic characteristics of the DNA found in the plasma of cancer patients | Q34543792 |
| | Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. | Q50882453 |
| | Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. | Q51752412 |
| | Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer. | Q53534876 |
| | Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. | Q54714698 |
| | Increased plasma DNA integrity in cancer patients. | Q54763921 |
| | Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. | Q54769141 |
| | Free DNA in the serum of cancer patients and the effect of therapy. | Q55492005 |
| | Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients | Q57240090 |
| | Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia | Q60305981 |
| | Changes in Concentration of DNA in Serum and Plasma during Storage of Blood Samples | Q62632521 |
| | Soluble normal and mutated DNA sequences from single-copy genes in human blood | Q72268467 |
| | The use of fluorometric assays to assess the immune response to DNA in murine systemic lupus erythematosus | Q73489250 |
| | The origin and mechanism of circulating DNA | Q73808680 |
| | Alu repeat sequences are present in increased proportions compared to a unique gene in plasma/serum DNA: evidence for a preferential release from viable cells? | Q77170479 |
| | Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients | Q77804773 |
| | Usefulness of analytical CEA doubling time and half-life time for overlooked synchronous metastases in colorectal carcinoma | Q77924833 |
| | Disappearance curves for tumor markers after resection of intrathoracic malignancies | Q77982209 |
| | Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer | Q82218655 |
| | Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease | Q84589922 |
| | Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression | Q87382252 |
| | Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma | Q38270678 |
| | Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma | Q38395321 |
| | Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer | Q38418038 |
| | Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays | Q39922627 |
| | Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade | Q42690704 |
| | Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma | Q43469202 |
| | Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. | Q43512551 |
| | DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. | Q43540280 |
| | Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing | Q44576396 |
| | Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer | Q44670943 |
| | Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma | Q45721923 |
| | Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma | Q46062133 |
| | Detection of ultrarare somatic mutation in the human TP53 gene by bidirectional pyrophosphorolysis-activated polymerization allele-specific amplification | Q46131826 |
| | ??? | Q94720111 |
| | DNA integrity assay: a plasma-based screening tool for the detection of prostate cancer | Q34555788 |
| | Prediction of breast tumor progression by integrity of free circulating DNA in serum. | Q34565015 |
| | Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? | Q34577740 |
| | If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells | Q34625589 |
| | Prediction of clear cell renal cell carcinoma by integrity of cell-free DNA in serum | Q35016114 |
| | Identification of an intracellular precursor to DNA excreted by human lymphocytes | Q35024389 |
| | Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors | Q35132293 |
| | Tumor clone dynamics in lethal prostate cancer | Q35575930 |
| | Genomic analysis of circulating cell-free DNA infers breast cancer dormancy | Q35694373 |
| | Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus | Q35763885 |
| | Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA | Q35810461 |
| | Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer | Q35879064 |
| | Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients | Q35995428 |
| | Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease | Q36000803 |
| | Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool | Q36372817 |
| | Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood | Q36497457 |
| | Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients | Q36618056 |
| | Circulating nucleic acids (CNAs) and cancer--a survey | Q36669780 |
| | Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance | Q36719984 |
| | Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. | Q36998629 |
| | Detection, clinical relevance and specific biological properties of disseminating tumour cells | Q37135356 |
| | The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients | Q37225239 |
| | Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy | Q37286893 |
| | Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer | Q37765189 |
| | Circulating tumour cells in cancer patients: challenges and perspectives | Q37776363 |
| | Cell-free DNA in the circulation as a potential cancer biomarker. | Q37903558 |
| | Overcoming implementation challenges of personalized cancer therapy | Q38031117 |
| | DNA methylation profiling in the clinic: applications and challenges | Q38040319 |
| | Circulating tumor cells: liquid biopsy of cancer | Q38046735 |
| | The implications of clonal genome evolution for cancer medicine | Q38085043 |
| | Circulating tumour cells and cell-free DNA as tools for managing breast cancer | Q38109808 |
| | Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. | Q38152782 |
| | Technologies for detection of circulating tumor cells: facts and vision | Q38154493 |
| | Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance | Q38249332 |
| | Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? | Q38261856 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neoplasm | Q1216998 |
| | tumor biomarker | Q66205818 |
| | neoplasm DNA | Q71515340 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 36 | |
| P577 | publication date | 2016-04-07 | |
| P1433 | published in | Chinese Journal of Cancer | Q15760211 |
| P1476 | title | Cell-free circulating tumor DNA in cancer | |
| P478 | volume | 35 | |